Shared decision-making moves exercise counseling beyond blanket restriction

Children and adolescents with congenital heart disease are surviving in far greater numbers, and that shift has changed what pediatric cardiology must deliver. Survival alone is no longer the central question. Quality of life, physical conditioning, and the ability to participate in ordinary childhood activities now sit beside it, especially for young people who have spent years being told to be careful, to sit out, or to avoid exertion altogether.

A nationwide Swedish cohort of more than 64,000 children with congenital heart disease reported 97% survival among those born between 2010 and 2017, with mortality still concentrated in the most complex lesions. Against that background, physical inactivity has emerged as an avoidable harm. In a 2025 multicenter study, moderate-to-vigorous physical activity averaged 42.0 minutes per day in children with inherited cardiac disease, compared with 48.2 minutes per day in healthy controls. The gap may look modest on paper; at the bedside, it means fewer play sessions, fewer sports, and more children growing up with reduced confidence in their own bodies.

Exercise restriction has long been driven by fear of arrhythmia, hemodynamic compromise, or sudden collapse during sport. Those concerns are real, but so is the cost of overprotection. Deconditioning erodes aerobic capacity, weakens social participation, and can leave families uncertain about what a child is actually allowed to do. When advice is vague or overly conservative, inactivity becomes the default rather than the exception.

One sentence captures the problem: avoidance can become its own morbidity.

A pilot clinic in France tested a more structured path

Petrault and colleagues introduced a pilot model for preventive sports cardiology in youth with heart disease through a prospective single-center study in France. The cohort included 34 participants aged 6 to 25 years with chronic cardiac conditions, including congenital heart disease, cardiomyopathies, and inherited arrhythmia syndromes. Each participant underwent a well-being assessment, a sports cardiology evaluation, and a shared decision-making consultation.

The design is important because it reframes the clinical encounter. Instead of asking only whether exercise is permitted, the clinic asked how to support safe and meaningful physical activity in daily life. Objective testing was paired with discussion of goals, fears, and expectations. Cardiopulmonary exercise testing, imaging, functional evaluation, and patient-reported outcomes were pulled into the same conversation, creating a plan that reflects both physiology and lived experience.

In practical terms, that structure addresses a common failure point in pediatric care: children and families often receive a risk label without a usable plan. A young person may know that exertion is “not recommended,” yet still not know whether they can walk to school, join gym class, or return to a favored sport. A multidisciplinary consultation gives those choices a clinical framework.

Aerobic fitness and perceived risk do not always match

The study also reflects a broader truth in pediatric cardiology: measured function and perceived limitation often diverge. Many participants demonstrated impaired aerobic fitness despite preserved cardiac function, suggesting that deconditioning contributes more than disease severity alone in at least some patients. CPET is useful precisely because it separates cardiovascular limitation from ventilatory or peripheral causes of exercise intolerance. It also gives families something concrete to discuss instead of relying on instinctive caution.

The clinical value here is not abstract. A child who has grown accustomed to low activity may have normal resting cardiac findings but poor exercise tolerance, which reinforces parental fear and further limits participation. Once that cycle starts, the child can become progressively less active even when the underlying lesion is stable. The assessment model used in the pilot study is designed to interrupt that pattern by translating test results into a tailored activity plan.

Safety, acceptance, and adherence defined the early signal

The pilot program was feasible, well accepted, and associated with adherence of 82% at six months. No exercise-related adverse events occurred, and satisfaction scores were high among patients, families, and referring cardiologists. Those findings matter because they address the hesitation that often keeps exercise counseling conservative: if clinicians can structure recommendations carefully and monitor them, the discussion becomes safer and more credible.

The absence of exercise-related serious adverse events is especially meaningful in a setting where fear can dominate decision-making. It does not mean risk disappears. It does mean that a more individualized model can be delivered without obvious harm in this small cohort.

Shared decision-making has to work for parents, not only clinicians

Shared decision-making already has a growing role in cardiovascular care, where it improves knowledge, reduces decisional conflict, and strengthens adherence. Pediatric sports cardiology is more complicated than adult care because the decision usually involves the child, the parents, and the clinician at the same time. Those parties may not want the same outcome. A parent may lean toward restriction after hearing any mention of arrhythmia risk, while an adolescent may be eager to return to competition and accept more uncertainty.

The pilot clinic brought those perspectives into the open instead of leaving them implicit. That approach fits pediatric practice better than a one-way clearance model. It also preserves the physician’s responsibility to judge risk, document uncertainty, and define safe boundaries. Shared decision-making does not replace clinical judgment; it organizes it.

Building from the QUALIREHAB trial into routine care

The clinic also sits on the foundation of the multicenter QUALIREHAB trial, which used a 12-week hybrid cardiac rehabilitation program in adolescents and young adults with congenital heart disease. In that randomized trial, the intervention improved health-related quality of life, physical activity, and disease knowledge. The present implementation model keeps the trial’s logic alive by preserving patient-reported outcomes and CPET in everyday care.

That continuity matters because many rehabilitation benefits are lost once a study ends and patients return to routine follow-up. A clinic model that keeps testing, discussion, and counseling together gives those gains a better chance of lasting beyond the trial setting. It also creates a more realistic bridge between pediatric and adult cardiac sports guidance, where expectations often change abruptly as patients age.

Exercise advice in youth with heart disease should not be reduced to permission or prohibition. The better question is how to help a child or adolescent move safely, stay engaged, and understand the reasons behind the plan. This pilot suggests that structured shared decision-making can do that without sacrificing safety, while also exposing how much of the inactivity burden stems from uncertainty, not only from cardiac physiology.

The remaining challenge is scale: whether a single-center model can be reproduced across broader pediatric cardiology settings with different staffing, resources, and patient populations is still unanswered.

Citations and Trial Identifiers

Primary study DOI

The pilot study by Petrault and colleagues is indexed at DOI 10.1038/s41390-026-05012-5.

Related studies cited in the article

The Brazilian and international background literature cited in the source includes DOI-linked studies on survival, activity patterns, shared decision-making, and congenital heart disease rehabilitation:

  • 10.1161/JAHA.120.017704
  • 10.1001/jamanetworkopen.2024.61795
  • 10.1161/JAHA.116.004665
  • 10.1038/s41390-026-05012-5
  • 10.1038/s41390-026-05012-5
  • 10.1161/CIRCULATIONAHA.123.064318
  • 10.1093/eurheartj/ehaa501
  • 10.1002/pbc.28974
  • 10.1093/eurheartj/ehaa601
  • 10.1093/eurheartj/ehad431

Reporting by Dr. Aishwarya N., MBBS for Medicine World Foundation, with additional data provided by British Journal of Cancer.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA